(12) **Translation of European patent specification**

(11) **NO/EP 2892550 B1**

(19) NO

NORWAY

(51) Int Cl.
A61K 39/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.05.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.12.18
(86)	European Application Nr.	13835291.9
(86)	European Filing Date	2013.09.06
(87)	The European Application's Publication Date	2015.07.15
(30)	Priority	2012.09.07, US, 201261698138 P 2013.02.26, US, 201361769581 P 2013.02.28, US, 201361770421 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Coherus Biosciences, Inc., 201 Redwood Shores Parkway Suite 200, Redwood City, CA 94065, USA
(72)	Inventor	MANNING, Mark, 4630 Sorrel Lane, Johnstown, CO 80534, USA PAYNE, Robert W., 221 Cleopatra Street, Fort Collins, CO 80525, USA

(54) Title **STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB**

(56) References Cited:

US-A1- 2012 028 877
US-A1- 2009 291 062
US-A1- 2010 278 822
WO-A2-2012/065072
WO-A2-2014/039903
NICHOLAS W WARNE ED - LEHR CLAUS-MICHAEL ET AL: "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 78, no. 2, 3 March 2011 (2011-03-03), pages 208-212, XP028203394, ISSN: 0939-6411, DOI: 10.1016/J.EJPB.2011.03.004 [retrieved on 2011-03-13]
Torben Laursen ET AL: "Pain Perception after Subcutaneous Injections of Media Containing Different Buffers", Basic & Clinical Pharmacology & Toxicology, vol. 98, no. 2, 1 February 2006 (2006-02-01), pages 218-221, XP055118277, ISSN: 1742-7835, DOI: 10.1111/j.1742-7843.2006.pto_271.x

WANG W ET AL: "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 96, no. 1, 1 January 2007 (2007-01-01), pages 1-26, XP009084505, ISSN: 0022-3549, DOI: 10.1002/JPS.20727
"Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations [Elektronische Ressource]", PAPDEOTT00,, 6 February 2013 (2013-02-06), page 10pp, XP009188701,

Patentkrav

1. Vandig farmasøytisk sammensetning som består av:

(A)

(i) 50 mg/ml adalimumab,

(ii) 10 mM histidinbuffer,

(iii) 120 mM glysin,

(iv) 120 mM arginin, og

(v) 0,1 vekt-% polysorbat 80;

(B)

(i) 50 mg/ml adalimumab,

(ii) 10 mM histidinbuffer,

(iii) 120 mM glysin,

(iv) 120 mM arginin, og

(v) 0,05 vekt-% polysorbat 80;

(C)

(i) 50 mg/ml adalimumab,

(ii) 10 mM histidinbuffer,

(iii) 120 mM glysin,

(iv) 120 mM arginin, og

(v) 0,01 vekt-% polysorbat 80;

(D)

(i) 50 mg/ml adalimumab,

(ii) 10 mM histidinbuffer,

(iii) 120 mM glysin,

(iv) 120 mM arginin, og

(v) 0,05 vekt-% polysorbat 20;

(E)

(i) 50 mg/ml adalimumab,

(ii) 10 mM histidinbuffer,

(iii) 120 mM glysin,

(iv) 120 mM arginin, og

(v) 0,1 vekt-% Pluronic F-68;

(F)

(i) 50 mg/ml adalimumab,

(ii) 20 mM histidinbuffer,

(iii) 150 mM glysin,

(iv) 100 mM arginin, og

(v) 0,01 vekt-% polysorbat 80; eller
(G)
(i) 50 mg/ml adalimumab,
(ii) 20 mM histidinbuffer,
(iii) 120 mM glysin,
(iv) 120 mM arginin, og
(v) 0,01 vekt-% polysorbat 20;
hvori hver av (A)-(G) har en pH på 5,2.

2. Sammensetning for anvendelse i en fremgangsmåte for å behandle en inflammatorisk tilstand hos et individ, hvori fremgangsmåten omfatter administrering av en terapeutisk effektiv mengde av den farmasøytiske sammensetningen ifølge krav 1.